Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Continuous Marketing Application Pilot Program Is 44% Enrolled

Executive Summary

Enrollment in FDA's second continuous marketing application pilot program is nearly 50% enrolled

You may also be interested in...



BIO Suggests Re-Evaluation Of Continuous Marketing Application Programs

FDA's continuous marketing application pilot programs may not be worth continuing, the Biotechnology Industry Organization suggested

BIO Suggests Re-Evaluation Of Continuous Marketing Application Programs

FDA's continuous marketing application pilot programs may not be worth continuing, the Biotechnology Industry Organization suggested

FDA Finalizing Review Principles Guidance; Complete Submissions Urged

FDA's guidance on good review management principles is entering the final clearance stage, Office of New Drugs Director John Jenkins, MD, said during the Drug Information Association annual meeting in Washington, D.C. June 16

Related Content

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel